The basic idea is that admission to presymptomatic KP/PD information sets, efficacy and safety for drug research and molding.
The way this works is that More Than 500 presymptomatic modelings were tested on 100K+ Compounds with standardized evaluation standards, protocols and quality controls to let reliable analysis.
Preclinical data, research-ready.
See Dataset DocumentationPlasma exposure, efficacy curves, biomarker modulation included.
A central concept is that of dose-effect proportions, exposure-impression modelling data, and PD biomarkers for species and disease modelling for prospective moulding.
Explore PK/PD DataOncology, inflammation, CNS, metabolic diseases covered.
Basically, humanized shiner, genetically modified examples and syngenetic neoplasms with histopathology, tomography and documented selection points.
View Model LibraryRaw data, analysis files, protocols preserved.
The basic idea is that study reports, including statistical answers, guidance of dose selection and validation documents for analysis, assure the reliability of regulative strata.
Learn About Quality